...
首页> 外文期刊>Biochemistry >Interaction of Cardiac Troponin C with Ca~(2+) Sensitizer EMD 57033 and Cardiac Troponin I Inhibitory Peptide
【24h】

Interaction of Cardiac Troponin C with Ca~(2+) Sensitizer EMD 57033 and Cardiac Troponin I Inhibitory Peptide

机译:心肌钙蛋白C与Ca〜(2+)增敏剂EMD 57033和心肌钙蛋白I抑制肽的相互作用

获取原文
获取原文并翻译 | 示例
           

摘要

The binding of Ca~(2+) to cardiac troponic C (cTnC) triggers contraction in cardiac muscle. In diseased heart, the myocardium is often desensitized to Ca~(2+), leading to weak cardiac contractility. Compounds that can sensitize cardiac muscle to Ca~(2+), would have potental therapeutic value in treating heart failure. The thiadiazinone derivative EMD 57033 is an identified ‘Ca~(2+) sensitizer', and cTnC is a potential target of the drug. In this work, we used 2D {~1H, ~(15)N}-HSQC NMR spectroscopy to monitor the binding of EMD 57033 to cTnC in the Ca~(2+) -saturated state. By mapping the chemical shift changes to the structure of cTnC, EMD 57033 is found to bind to the C-domain of cTnC. To test whether EMD 57033 competes with cardiac TnI (cTnI) for cTnC and interferes with the inhibitory function, we examined the interaction of cTnC with an inhibitory cTnI peptide (residues 128-147, cIp) in the absence and presence of EMD 57033, respectively. cTnC was also titrated with EMD 57033 in the presence of cIp. The results show that although both the drug and cIp interact with the C-domain of cTnC, they do not displace each other, suggesting noncompetitive binding sites for the two targets. Detailed chemical shift mapping of the binding sites reveals that the regions encompassing helix G-loop IV-helix H are more affected by EMD 57033, while residues located on helix E-loop III-helix F and the linker between sites III and IV are more affected by cIp. In both cases, the binding stoichiometry is 1:1. The binding affinities for the drug are 8.0+-1.8 and 7.4+-4.8#mu#M in the absence and presence of cIp, respectively, while those for the peptide are 78.2+-10.3 and 99.2+-30.0#mu#M in the absence and presence of EMD 57033, respectively. These findings suggest that EMD 57033 may exert its positive inotropic effect by not directly enhancing Ca~(2+) binding to the Ca~(2+) regulatory site of cTnC, but by binding to the structural domain of cTnC, modulating the interaction between cTnC and other thin filament proteins, and increasing the apparent Ca~(2+) sensitivity of the contractile system.
机译:Ca〜(2+)与心肌肌钙蛋白C(cTnC)的结合触发了心肌的收缩。在患病的心脏中,心肌常对Ca〜(2+)脱敏,导致心脏收缩力弱。能使心肌对Ca〜(2+)敏感的化合物在治疗心力衰竭方面具有潜在的治疗价值。噻二嗪酮衍生物EMD 57033是公认的“ Ca〜(2+)敏化剂”,而cTnC是该药物的潜在靶标。在这项工作中,我们使用2D {〜1H,〜(15)N} -HSQC NMR光谱法监测EMD 57033与Ca〜(2+)饱和状态下cTnC的结合。通过将化学位移变化映射到cTnC的结构,发现EMD 57033与cTnC的C结构域结合。为了测试EMD 57033是否与心脏TnI(cTnI)竞争cTnC并干扰抑制功能,我们检查了在没有EMD 57033存在的情况下cTnC与抑制性cTnI肽(残基128-147,cIp)的相互作用。 。在cIp存在的情况下,cTnC也用EMD 57033滴定。结果表明,尽管药物和cIp都与cTnC的C结构域相互作用,但它们不会彼此置换,提示这两个靶标具有非竞争性结合位点。结合位点的详细化学位移图谱表明,包围螺旋G环IV螺旋H的区域受EMD 57033的影响更大,而位于螺旋E环III螺旋F以及位点III和IV之间的连接基上的残基更多受cIp影响。在两种情况下,结合化学计量比均为1:1。在不存在和存在cIp的情况下,药物的结合亲和力分别为8.0 + -1.8和7.4 + -4.8#mu#M,而在肽中,对肽的结合亲和力为78.2 + -10.3和99.2 + -30.0#mu#M。 EMD 57033的存在与否。这些发现表明,EMD 57033可能通过不直接增强Ca〜(2+)与cTnC的Ca〜(2+)调控位点的结合,而是通过与cTnC的结构域结合,调节两者之间的相互作用来发挥其正性肌力作用。 cTnC和其他细丝蛋白,并增加收缩系统的表观Ca〜(2+)敏感性。

著录项

  • 来源
    《Biochemistry》 |2000年第30期|共9页
  • 作者

    Li Monica X.;

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号